Interleukin 10 production pathway (IL-10)

Interleukin 10 (IL‑10) is an anti-inflammatory cytokine encoded by the IL – *gene* on chromosome 1. It acts primarily by inhibiting proinflammatory cytokines produced by macrophages and T cells, thereby limiting tissue damage during infection or inflammation. Its biologically active form is a soluble homodimer that signals through a heterotetrameric receptor complex composed of two IL‑ receptor alpha subunits (IL‑ RA) and two beta subunits (IL‑ RB), activating JAK/STAT pathways—especially STAT3—to mediate transcriptional responses. While originally described as secreted mainly by Th₂ cells, it is now known that many myeloid and lymphoid cell types—including monocytes/macrophages, dendritic cells, regulatory T cells—can produce IL‐0 under various stimuli such as TLR ligands or other cytokines. Tight regulation at both transcriptional/post-transcriptional levels ensures appropriate immune balance; dysregulation contributes to autoimmunity if deficient but increases infection/cancer risk if excessive.[1][2] “The ‘interleukin 0 production pathway’ refers collectively to all cellular processes regulating expression/secretion/bioactivity of interleukin 0 rather than any single molecular entity.”

Other names

Human cytokine synthesis inhibitory factor (CSIF)IL10Cytokine synthesis inhibitory factorCSIF

For drugs aiming to increase IL‑10 activity: Enhancement of anti-inflammatory signaling by increasing endogenous/exogenous levels of interleukin 10. For inhibitors/modulators: Suppression or alteration of downstream STAT3/JAK/ERK pathways involved in immune regulation. Indirect mechanisms include upregulation via GPCRs such as beta‑adrenergic receptors and cannabinoid receptors.